Altre lingue Biovica International AB

Azioni

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:29:38 26/04/2024			Variaz. 5gg	Var. 1 gen.
1,706 ^SEK	+6,36%		-22,81%	-33,88%

12/04	Biovica International AB (Publ) annuncia Divitum® Tka in uno studio osservazionale	CI
11/04	Biovica International AB (Publ) annuncia le nomine al Comitato di Nomina	CI

Biovica saves SEK 30 million year and investigates new go-to market model in US	24/04
Biovica saves SEK 30 million/year and investigates new go-to market model in US	23/04
Biovica - DiviTum TKa in observational trial	15/04
DiviTum TKa in Observational Trial	15/04
Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024.	13/04
DiviTum® TKa in observational trial	12/04
Biovica International AB Announces Divitum® Tka in Observational Trial	12/04
Biovica International AB Announces Appointments to the Nomination Committee	11/04
Nomination Committee for Biovica International AB for the 2024 Annual General Meeting	11/04
Biovica receives positive patent notification for immunotherapies	19/03
Biovica - Commercial progress despite a quarter with modest sales	18/03
Q3 Interim Report November-January 2023/2024	14/03
Biovica International AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	14/03
Interventional DiviTum® TKa trial launches at Washington University	13/03
Biovica Announces Interventional DiviTum TKa Trial Launches at Washington University	13/03
Biovica International Signs SEK 1.2 Million Master Service Agreement	12/03
Biovica signs master service agreement	12/03
Biovica Signs Master Service Agreement for Tka Testing with Leading Pharma Company	07/03
Biovica signs master service agreement for TKa testing with leading pharma company	07/03
Biovica signs agreement with Palex Group, a market leader in Spain and Portugal	22/01

Non ci sono risultati per questa ricerca